SmartQuit and GSK collaborate to provide NRT to app users

PRESS RELEASE


KIRKLAND, Wash. – March 8, 2016 - 2Morrow Inc, makers of SmartQuit®, the first clinically proven app to help smokers quit, announced their collaboration with GlaxoSmithKline® (LSE/NYSE:GSK) to provide nicotine replacement therapy (NRT) to program participants. 

SmartQuit plus NRT

SmartQuit is an app-based program first developed by researchers at the Fred Hutchinson Cancer Research Center and has been tested in 2 clinical trials.* The program uses a unique Acceptance and Commitment Therapy (ACT) approach to help participants learn new ways to deal with the urge to smoke. In clinical trials, without NRT, smokers who used SmartQuit quit at rates that were 2-3 times higher than people trying on their own. SmartQuit is designed to use with or without quit medications such as the nicotine patch. www.2Morrowinc.com/smoking-cessation

“We know that combining behavioral programs like SmartQuit and NRT can increase a smoker's chances of quitting,” says Jo Masterson, COO of 2Morrow. “Our clients have been asking us to make it easier for smokers to get NRT with the SmartQuit program and this GSK collaboration will do that.” 
Most SmartQuit programs are offered by states, wellness programs or employers. Now those groups will be able to offer NRT to smokers via the app, increasing their odds of quitting. 

About 2Morrow, Inc. 
2Morrow, Inc is a mobile health (mHealth) developer dedicated to improving millions of lives with the use of evidence-based, behavioral change programs. We distribute our programs mostly through employers, states, wellness programs and health plans. SmartQuit is a smoking cessation program powered by 2Morrow’s behavior change engine and delivered via a mobile app. www.2Morrowinc.com/smoking-cessation

About GSK Consumer Healthcare.

SmartQuit Plus NRT

GSK Consumer Healthcare is one of the world's largest consumer healthcare companies. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products. We have a heritage that goes back over 160 years. We own some of the world’s best loved healthcare brands, including Sensodyne®, Theraflu®, Excedrin®, Nicorette® and NicoDerm® CQ®, Flonase®, and TUMS®. These brands are successful in over 100 countries around the world because they all show our passion for quality, guaranteed by science. They are inspired by the real wants and needs of the millions of people who walk into pharmacies, supermarkets, market stalls and go on-line all over the world every day, and choose us first.
 
Our goal is to build a global, growing business we call a Fast Moving Consumer Healthcare (FMCH) company, dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

Media Contact: 
Jo Masterson, COO at 2Morrow, Inc
jmasterson @ 2morrowinc.com

About 2Morrow, Inc. http://www.2morrowinc.com/about-us/
* Study information: http://www.2morrowinc.com/resources/
Learn more about SmartQuit: www.2Morrowinc.com/smoking-cessation